Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
LMWH prophylaxis vs UFH prophylaxis Symptomatic DVT · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | RR 0.67 [0.27, 1.69] | 8 studies · 2250 participants | Moderate |
LMWH prophylaxis vs UFH prophylaxis Symptomatic DVT measured as asymptomatic DVT · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | RR 0.86 [0.71, 1.05] | 12 studies · 4938 participants | Low |
LMWH prophylaxis vs UFH prophylaxis Major bleeding · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | RR 1.01 [0.69, 1.48] | 9 studies · 3473 participants | Moderate |
LMWH prophylaxis vs UFH prophylaxis Minor bleeding · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | RR 1.01 [0.76, 1.33] | 2 studies · 1194 participants | Moderate |
LMWH prophylaxis vs UFH prophylaxis Wound hematoma · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | RR 0.7 [0.54, 0.92] | 6 studies · 2827 participants | Moderate |
LMWH prophylaxis vs UFH prophylaxis Reoperation for bleeding · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | RR 0.93 [0.57, 1.5] | 4 studies · 1246 participants | Moderate |
LMWH prophylaxis vs UFH prophylaxis Intraoperative transfusion · People with cancer with perioperative thromboprophylaxis Anticoagulation for perioperative thromboprophylaxis in people with cancer (2018) · Cochrane | no estimate extracted | 2 studies · 737 participants | Low |
Exercise interventions vs usual care Aerobic exercise tolerance (all cancers: 8 to 12 weeks of Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 10 studies · 604 participants | Low |
Exercise interventions vs usual care Aerobic exercise tolerance (all cancers: 8 to 12 weeks of Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 4 studies · 201 participants | Low |
Exercise interventions vs usual care Aerobic exercise tolerance (all cancers: 6 months) Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 7 studies · 591 participants | Low |
Exercise interventions vs usual care Aerobic exercise tolerance (breast cancer: 8‐12 weeks of Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 6 studies · 441 participants | Very low |
Exercise interventions vs usual care Aerobic exercise tolerance (all cancers: combination of supervised and home‐based exercise: 8 to 12 weeks of Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 4 studies · 357 participants | Very low |
Exercise interventions vs usual care Aerobic exercise tolerance (all cancers: home‐based exercise: 8 to 12 weeks of Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 3 studies · 155 participants | Very low |
Exercise interventions vs usual care Aerobic exercise tolerance (all cancers:supervised exercise: 8 to 12 weeks of Interventions for promoting habitual exercise in people living with and beyond cancer (2018) · Cochrane | no estimate extracted | 3 studies · 92 participants | Very low |
Moxibustion vs no treatment The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | RR 0.5 [0.1, 2.56] | 1 study · 72 participants | Low |
Moxibustion vs sham treatment Patient‐reported symptom: nausea/vomiting (EORTC QLQ‐C30) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Moxibustion vs sham treatment Patient‐reported symptom: diarrhoea (EORTC QLQ‐C30) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Moxibustion vs sham treatment Objective outcome measure: WBC count (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 1.72 [0.97, 2.47] | 1 study · 50 participants | Low |
Moxibustion vs sham treatment Objective outcome measure: haemoglobin (g/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 2.06 [1.26, 2.86] | 1 study · 50 participants | Low |
Moxibustion vs sham treatment Objective outcome measure: platelets (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 210.79 [167.02, 254.56] | 1 study · 50 participants | Low |
Moxibustion vs conventional medicines The incidence and severity of toxicities: haematological toxicity · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | RR 0.57 [0.15, 2.2] | 1 study · 72 participants | Low |
Moxibustion vs conventional medicines QoL (Karnofsky score) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 6.7 [2.37, 11.03] | 1 study · 82 participants | Low |
Moxibustion vs conventional medicines Patient‐reported symptom: nausea/vomiting · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs conventional medicines Patient‐reported symptom: diarrhoea · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs conventional medicines Objective outcome measure: WBC count (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 0.4 [0.15, 0.65] | 1 study · 90 participants | Low |
Moxibustion vs no treatment QoL · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs conventional medicines Objective outcome measure: haemoglobin (g/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 10.28 [4.51, 16.05] | 2 studies · 235 participants | Low |
Moxibustion vs conventional medicines Objective outcome measure: platelets (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | 2 studies · 210 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | RR 0.14 [0.01, 2.64] | 1 study · 56 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone QoL (EORTC QLQ‐c30) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 8.85 [4.25, 13.46] | 3 studies · 134 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone Patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | RR 0.43 [0.25, 0.74] | 7 studies · 801 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone Patient‐reported symptom: diarrhoea · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | RR 0.19 [0.01, 3.88] | 1 study · 61 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone Objective outcome measure: WBC count (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | 3 studies · 262 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone Objective outcome measure: haemoglobin (g/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 3.97 [1.4, 6.53] | 2 studies · 142 participants | Low |
Moxibustion + conventional treatment vs conventional medicine alone Objective outcome measure: platelet (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 13.48 | 2 studies · 142 participants | Low |
Moxibustion vs no treatment Patient‐reported symptom: nausea/vomiting · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs no treatment Patient‐reported symptom: diarrhoea · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs no treatment Objective outcome measure: WBC count (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 1.77 [0.76, 2.78] | 1 study · 80 participants | Low |
Moxibustion vs no treatment Objective outcome measure: haemoglobin (g/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 1.33 [1.2, 1.46] | 1 study · 66 participants | Low |
Moxibustion vs no treatment Objective outcome measure: platelets (× 109/L) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs sham treatment The incidence and severity of chemotherapy‐ or radiotherapy‐related toxicities · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxibustion vs sham treatment QoL (EORTC QLQ‐C30) · patients receiving chemotherapy or radiotherapy for cancer treatment Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer (2018) · Cochrane | MD 14.88 [4.83, 24.93] | 1 study · 50 participants | Low |
Pharmacological intervention vs no intervention Insufficiency fractures and avascular necrosis · Adults undergoing pelvic radiotherapy Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis… (2018) · Cochrane | no estimate extracted | 905 participants | Very low |
Pharmacological intervention vs no intervention BMD and fracture risk · Adults undergoing pelvic radiotherapy Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis… (2018) · Cochrane | no estimate extracted | 905 participants | Very low |
Pharmacological intervention vs no intervention Bone turnover markers · Adults undergoing pelvic radiotherapy Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis… (2018) · Cochrane | no estimate extracted | 905 participants | Very low |
Pharmacological intervention vs no intervention QoL · Adults undergoing pelvic radiotherapy Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis… (2018) · Cochrane | no estimate extracted | 905 participants | Very low |
Pharmacological intervention vs no intervention Mortality · Adults undergoing pelvic radiotherapy Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis… (2018) · Cochrane | no estimate extracted | 905 participants | Very low |
Pharmacological intervention vs no intervention Adverse events · Adults undergoing pelvic radiotherapy Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis… (2018) · Cochrane | no estimate extracted | 905 participants | Very low |
Chemoradiotherapy vs radical surgery Overall survival (5‐year) · women (18 years and older) diagnosed with stage IB2 cervical cancer Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage… (2018) · Cochrane | no estimate extracted | NR | Very low |
Chemoradiotherapy vs radical surgery Progression‐free survival (5‐year) · women (18 years and older) diagnosed with stage IB2 cervical cancer Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage… (2018) · Cochrane | no estimate extracted | NR | No studies |